Evidence map›Paper›PMID 21804357›Full record

ArticleGut microbes

The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile Infection.

Angela E Reeves, Casey M Theriot, Ingrid L Bergin, Gary B Huffnagle, Patrick D Schloss, Vincent B Young

Open access · bronzeAbstract read
In one paragraph

Article in Gut microbes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 188 papers.

0numbers the graph read from it
0cells of the map it votes in
188citing papers in PubMed
11.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

188 citing papers in PubMed, 279 citations in OpenAlex.

  1. Article
  2. Phase variable colony morphotypes ofInfection and immunity · 2026
    Article
  3. Visualizing C. difficile During Murine Infection.Methods in molecular biology (Clifton, N.J.) · 2026
    Article
  4. Article
  5. Unravelling three-way interactions betweenJournal of medical microbiology · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Roles of Gut Microbiota and Associated Metabolites inPolish journal of microbiology · 2025
    Article
  10. Article
  11. Gut Microbiota and New Microbiome-Targeted Drugs forAntibiotics (Basel, Switzerland) · 2024
    Review
  12. Article
  13. Review
  14. Article
  15. The state of play of rodent models for the study ofJournal of medical microbiology · 2024
    Review
  16. Article
  17. Article
  18. Reviewing theMicroorganisms · 2024
    Review
  19. Article
  20. Article

128 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Angela E ReevesDepartment of Microbiology & Immunology, The University of Michigan, Ann Arbor, MI, 48109, USA.
Casey M Theriot
Ingrid L Bergin
Gary B Huffnagle
Patrick D Schloss
Vincent B Young
University of Michigan–Ann Arbor · US

Funding

The Interplay Between Host Immunity and Clostridium difficile PathogenesisU19AI090871 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI YOUNG, VINCENT B · 2010 to 2014
$7.5M
Molecular Mechanisms of Microbial Pathogenesis Training ProgramT32AI007528 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CARRUTHERS, VERNON BRUCE · 1998 to 2024
$6.8M
Microbial Ecology of Helicobacter-induced ColitisR01DK070875 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI YOUNG, VINCENT B · 2007 to 2011
$1.4M
Identifying population-level variation in cross-sectional and longitudinal HMP stR01HG005975 · NHGRI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SCHLOSS, PATRICK DAVID · 2010 to 2012
$1.1M
Mucosal Mechanisms Linking Pulmonary and Gastrointestinal Inflammation/ImmunityR21AI083473 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HUFFNAGLE, GARY B · 2009 to 2010
$412k
NHGRI NIH HHS HG005975NHGRI NIH HHS R01 HG005975NIAID NIH HHS AI07528NIAID NIH HHS AI083473NIAID NIH HHS AI090871NIAID NIH HHS R21 AI083473NIAID NIH HHS T32 AI007528NIAID NIH HHS U19 AI090871NIDDK NIH HHS DK070875NIDDK NIH HHS R01 DK070875
6 · The paper itself

Abstract

Clostridium difficile infection (CDI) arises in the setting of antibiotic administration where disruption of the normal indigenous gut microbiota leads to susceptibility to C. difficile colonization and colitis. Using a murine model of CDI, we demonstrate that changes in the community structure of the indigenous gut microbiota are associated with the loss of colonization resistance against C. difficile. Several antibiotic regimens were tested in combination for the ability to overcome colonization resistance, including a five antibiotic cocktail consisting of kanamycin, gentamicin, colistin, metronidazole, and vancomycin administered in drinking water for three days, a single intraperitoneal dose of clindamycin or 10 days of cefoperazone in drinking water. Following antibiotic treatment animals were challenged with 105 colony forming units of C. difficile strain VPI 10463 via oral gavage. Animals that received the antibiotic cocktail and clindamycin prior to C. difficile challenge followed one of two clinical courses, either becoming clinically ill and moribund within 2-4 days post challenge, or remaining clinically well. Animals that became clinically ill developed histologically severe colitis. These histopathologic findings were significantly less severe in animals that remained clinically well. Analysis of 16S rRNA gene sequences retrieved from gut tissue at necropsy demonstrated that Proteobacteria dominated the gut microbiota in clinically ill animals. In contrast, the gut microbial community of clinically well animals more closely resembled untreated animals, which were dominated by members of the Firmicutes. All animals that received cefoperazone treatment prior to C. difficile challenge were clinically ill and moribund by 2-5 days post challenge in a dose dependent manner. The gut communities in these animals were dominated by C.difficile suggesting that cefoperazone treatment resulted in a greater loss in colonization resistance. Thus, the severity of colitis that arises in this system reflects the interplay between the expansion of C. difficile in the gut community and the ecologic dynamics of the indigenous microbial community as it recovers from antibiotic perturbation. We demonstrate that altering the balance of these two opposing processes alters clinical outcome and thus may lead to novel preventative and therapeutic approaches for CDI.

Indexed as

MetagenomeAnimalsAnti-Bacterial AgentsBacteriaClostridioides difficileClostridium InfectionsColitisDisease Models, AnimalGastrointestinal TractHumansMiceMice, Inbred C57BLAnti-Bacterial Agents

Identifiers

PMID21804357
PMCPMC3225775
OpenAlexW2069894149

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.